Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-05-01T00:11:58.623Z Has data issue: false hasContentIssue false

Chapter 3 - Pharmacology and unique side effects of hormonal therapy in older adults

from Part 1 - Key principles in geriatric oncology

Published online by Cambridge University Press:  05 August 2011

By
Leona Downey
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 32 - 40
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Jin, Y, Desta, Z, Stearns, V. CYP2D6 genotype, anti-depressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30–39.CrossRefGoogle Scholar
Hemeryck, A, Belpaire, FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug interactions: an update. Curr Drug Metab. 2002;3(1):13–37.CrossRefGoogle ScholarPubMed
Schroth, W, Antoniadou, L, Fritz, P. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clinical Oncology 2007;25(33):5187–5193.CrossRefGoogle ScholarPubMed
Goetz, MP, Knox, SK, Suman, VJ. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113–121.CrossRefGoogle ScholarPubMed
,Defining genetic influences on pharmocologic responses. Indiana University School of Medicine Web site. Available at: http://www.drug-interactions.com.
Braithwaite, RS, Chlebowski, RT, Lau, J. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937–947.CrossRefGoogle ScholarPubMed
Ragaz, J, Coldman, A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol. 1998;16(6):2018–2024.CrossRefGoogle ScholarPubMed
Howell, A, Cuzick, J, Baum, M. Results of the ATAC (arimidex, tamoxifen alone or in combination) trial after completion of 5 years'; adjuvant treatment for breast cancer. Lancet. 2005;365:60–62.Google ScholarPubMed
Coombes, RC, Hall, E, Gibson, LJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092.CrossRefGoogle Scholar
Jakesz, R, Jonat, W, Gnant, M. Switching of post-menopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years'; adjuvant tamoxifen: combined results of the ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462.CrossRefGoogle Scholar
Markovitch, O, Tepper, R, Fishman, A. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in post-menopausal breast cancer patients. Breast Cancer Res Treat. 2007;101(2):185–190.CrossRefGoogle Scholar
Grady, D, Yaffe, K, Kristof, M. Effect of post-menopausal hormone therapy on cognitive function: the Heart and Estrogen/Progestin Replacement Study. Am J Med. 2002;113(7):543–548.CrossRefGoogle Scholar
Shumaker, SA, Legault, C, Kuller, L. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc. 2004;291(24):2947–2958.CrossRefGoogle ScholarPubMed
Ernst, T, Chang, L, Cooray, D. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94(8):592–597.CrossRefGoogle ScholarPubMed
Yaffe, K, Krueger, K, Cummings, SR. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005;162(4):683–690.CrossRefGoogle ScholarPubMed
Jenkins, VA, Shilling, V, Fallowfield, L. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61–66.CrossRefGoogle ScholarPubMed
Bender, CM, Sereika, SM, Brufsky, AM. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14(6):995–998.CrossRefGoogle ScholarPubMed
Jenkins, VA, Ambroisine, LM, Atkins, L. Effects of anastrozole on cognitive performance in postmenopausal women: a randomized, double blind chemoprevention trial (IBIS II). Lancet Oncol. 2008;9:953–961.CrossRefGoogle Scholar
Cummings, FJ, Gray, R, Davis, TE. Tamoxifen versus placebo: double blind adjuvant trial in elderly women with stage II breast cancer. NCI Monogr. 1986;1:119–123.Google Scholar
Toulis, KA, Tzellos, T, Kouvelas, D. Gabapentin for the treatment of hot flushes in women with natural or tamoxifen induced menopause: a systematic review and meta-analysis. Clin Therap. 2009;31(2):221–235.CrossRefGoogle ScholarPubMed
Buijs, C, Mom, CH, Willemse, PH. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat. 2009;115(3):573–580.CrossRefGoogle ScholarPubMed
Muss, H, Tu, D, Ingle, JN. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTC Intergroup Trial MA.17. J Clin Oncol. 2008;26(12):1956–1964.CrossRefGoogle ScholarPubMed
,Consensus Development Statement. Who are candidates for prevention and treatment of osteoporosis?Osteoporos Int. 1997;7:1–6.CrossRefGoogle Scholar
Eastell, R, Adams, JE, Coleman, RE. Effect of anastrozole on bone mineral density: 5-year result from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051–1057.CrossRefGoogle ScholarPubMed
Coleman, RE, Banks, LM, Girgis, SI. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in post-menopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled trial. Lancet Oncol. 2007;8:119–127.CrossRefGoogle Scholar
Crivellari, D, Sun, Z, Coates, AS. Letrozole versus tamoxifen for elderly patients with endocrine responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008;28(12):1972–1979.CrossRefGoogle Scholar
ATAC Trialists'; group effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100 month analysis of the ATAC trial. Lancet Oncol. 2007;9:45–53.
Brufsky, A, Bundred, N, Coleman, R. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor associated bone loss in post-menopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008;13:503–514.CrossRefGoogle Scholar
Ellis, GK, Bone, HG, Chlebowski, R. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–4882CrossRefGoogle ScholarPubMed
Gnant, M, Mlineritsch, B, Schippinger, W. Endocrine therapy plus zoledronic acid in pre-menopausal breast cancer. New Engl J Med. 2009; 360: 679–691.CrossRefGoogle Scholar
Crew, KD, Greenlee, H, Capodice, J. Prevalence of joint symptoms in post-menopausal women taking aromatase inhibitors for early stage breast cancer. J Clin Oncol. 2007;25(25):3877–3883.CrossRefGoogle Scholar
Sestak, I, Cuzick, J, Sapunar, F. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9:866–872.CrossRefGoogle ScholarPubMed
Morales, L, Pans, S, Verschueren, K. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008;26(19):3147–3152.CrossRefGoogle ScholarPubMed
Thurlimann, B, Keshaviah, A, Coates, AS, (BIG 1-98 Collaborative Group). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–2757.Google ScholarPubMed
,ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC trial. Lancet. 2002;359:2131–2139.CrossRefGoogle Scholar
Filippatos, TD, Liberopoulos, EN, Pavlidis, N. Effect of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev. 2009;35,2: 175–184.CrossRefGoogle Scholar
Cuppone, F, Bria, E, Verma, S. Do adjuvant aromatase inhibitors increase the cardiovascular risk in post-menopausal women with early breast cancer: a meta-analysis of published trials. Cancer. 2008;112(2):260–267.CrossRefGoogle Scholar
Chapman, JW, Meng, D, Shepherd, L. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008;100(4):252–260.CrossRefGoogle ScholarPubMed
Derzko, C, Elliott, S, Lam, W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 2007;14(suppl 1):20–40.Google ScholarPubMed
Kendall, A, Dowsett, M, Folkerd, E. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584–587.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×